Briefing to the OPTN Board of Directors on
Ongoing Review of National Liver Review Board (NLRB) Diagnoses

OPTN Liver and Intestinal Organ Transplantation Committee

Contents
Executive Summary 2
Purpose 4
Background 4
Proposal for Board Consideration 5
Overall Sentiment from Public Comment 12
Compliance Analysis 13
Implementation Considerations 15
Post-implementation Monitoring 17
Conclusion 17
Policy and Guidance Language 19
Ongoing Review of National Liver Review Board (NLRB) Diagnoses

Affected Policies:
- Policy 9.5.I.i: Initial Assessment and Requirements for HCC Exception Requests
- Policy 9.5.I.ii: Eligible Candidates Definition of T2 Lesions
- Policy 9.5.I.iii: Lesions Eligible for Downstaging Protocols
- Policy 9.5.I.iv: Candidates with Alpha-fetoprotein (AFP) Levels Greater than 1000
- Policy 9.5.I.v: Requirements for Dynamic Contrast-enhanced CT or MRI of the Liver
- Policy 9.5.I.vi: Imaging Requirements for Class 5 Lesions
- Policy 9.5.I.vii: Extensions of HCC Exceptions

Affected Guidance:
- Guidance to Liver Transplant Programs and the National Liver Review Board for Adults MELD Exceptions for Hepatocellular Carcinoma (HCC)
- Guidance to Liver Transplant Programs and the National Liver Review Board for Adults MELD Exception Review

Sponsoring Committee: Liver and Intestinal Organ Transplantation

Public Comment Period: January 27, 2022 – March 23, 2022

Board of Directors Meeting: June 27, 2022

Executive Summary

This proposal includes four updates to OPTN policy and guidance related to the National Liver Review Board (NLRB).

The purpose of the NLRB, which the OPTN implemented on May 14, 2019, is to provide equitable access to transplant for liver candidates whose calculated model for end-stage liver disease (MELD) score or pediatric end-stage liver disease (PELD) score does not accurately reflect the candidate’s medical urgency for transplant.1 This proposal seeks to make improvements to the NLRB policy and guidance documents, including the following changes:

- **Hepatocellular Carcinoma (HCC) policy**: Update policy language to align with Liver Imaging Reporting and Data System (LI-RADS) terminology and classifications.2 These changes will ensure the transplant community is using a consistent lexicon for HCC imaging.

- **HCC Guidance**: Simplify guidance for candidates who had HCC that was treated and subsequently recurs. The proposed changes will provide a more consistent and equitable pathway for these candidates to receive a MELD exception.

- **Ischemic Cholangiopathy (IC) Guidance**: Recommend candidates meeting criteria for an exception be provided a score equal to median MELD at transplant (MMaT). Because IC is a

---


2 See CT/MRI LI-RADS v2018 Core available at acr.org.
complication associated with livers from donation after cardiac death (DCD) donors, this proposed change will allow these candidates to access retransplant more quickly.

- **Polycystic liver disease (PLD) guidance**: Add a more objective definition for moderate to severe protein calorie malnutrition, add sarcopenia as a qualifying comorbidity, remove unnecessary language, and recommend all candidates meeting criteria be considered for MMaT. These changes will ensure that the appropriate candidates are able to access an exception and will increase equity in access to transplant for all PLD candidates.
Purpose

The purpose for updating NLRB policy and guidance is to continue to improve the NLRB by creating a more efficient and equitable system for reviewing MELD and PELD exception requests. These changes ensure that guidance and policy language remain clear and aligned with current research so the appropriate candidates receive MELD or PELD exceptions.

Background

When being listed for a liver transplant, candidates receive a calculated MELD or PELD score, which is calculated using a combination of the candidate’s clinical lab values. These scores are designed to reflect the probability of death on the waitlist within a 90-day period, with higher scores indicating a higher probability of mortality and increased urgency for transplant. Candidates who are less than 12 years old receive a PELD score, while candidates who are at least 12 years old receive a MELD score. Candidates that are particularly urgent are assigned status 1A or 1B.

When a transplant program believes that a candidate’s calculated MELD or PELD score does not accurately reflect a candidate’s medical urgency, they can request a score exception. The NLRB is responsible for reviewing exception requests and either approving or denying the requested score.

Under the NLRB, candidates who meet the criteria outlined in OPTN policy for one of the nine standardized diagnoses are eligible to have their exception automatically approved. In addition, each of the three specialty review boards (Pediatric, Adult - Hepatocellular Carcinoma (HCC), and Adult - Other Diagnosis) has an associated guidance document. The guidance documents contain information for review board members and transplant programs on diagnoses and clinical situations not included as one of the standardized diagnoses in policy. They provide recommendations on which candidates should be considered for a MELD or PELD exception and are based on published research, clinical guidelines, medical experience, and data. The documents are intended to help ensure consistent and equitable review of exception cases and are not OPTN policy.

Because of this process, the Committee is proposing updates to OPTN policy related to HCC, as well as guidance for HCC, IC, and PLD. The review process included reviewing recent literature, identifying ambiguity in current guidance, reviewing cases that were appealed to the Appeals Review Team (ART), consulting with subject matter experts, and reviewing updated data, as needed. In addition to the changes included in this proposal, the Committee reviewed current guidance for post-transplant complications and the policy for hyperoxaluria and is not recommending any changes at this time.

---

3 The calculations for the MELD and PELD scores can be found in OPTN Policy, Available at https://optn.transplant.hrsa.gov/.
4 See OPTN Policy 9.5: Specific Standardized MELD or PELD Exceptions, Available at https://optn.transplant.hrsa.gov/
5 NLRB Guidance Documents are available at https://optn.transplant.hrsa.gov/
Proposal for Board Consideration

HCC Policy

The Committee is proposing a number of updates to OPTN policy to align with the terminology used by the American College of Radiology. The proposed updates do not change which candidates will be approved for an HCC exception. Rather, the new language will align OPTN terminology with the terminology used by radiologists as documented in the LI-RADS v2018 manual. The Committee drafted the proposed changes in consultation with leaders from the American College of Radiology who are subject matter experts in this area. The updated policy will allow the liver transplant community to use a consistent lexicon for the classification of HCC lesions. The changes should simplify the work of transplant coordinators, who currently must translate between the terms used by radiologists and the terms used by the liver transplant team. Aligning the terminology between these groups will reduce the chance of data entry error.

This aspect of the proposal was supported throughout public comment and only clarifying, non-substantive post-public comment changes were made.

A summary of the proposed changes is included in Table 1 below.

Table 1: Overview of Proposed Changes to HCC Policy

<table>
<thead>
<tr>
<th>Current Language</th>
<th>Proposed Language</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local regional</td>
<td>Locoregional</td>
</tr>
<tr>
<td>Lesions</td>
<td>Class 5 lesions</td>
</tr>
<tr>
<td>T2 lesions</td>
<td>T2 Stage</td>
</tr>
<tr>
<td>Residual Lesions</td>
<td>Viable Lesions</td>
</tr>
<tr>
<td>CT or MRI</td>
<td>Dynamic-contrast enhanced CT or MRI</td>
</tr>
<tr>
<td>Scan is inadequate or incomplete</td>
<td>Lesion cannot be categorized due to image degradation or omission</td>
</tr>
<tr>
<td>OPTN Class 0</td>
<td>NC - Not Categorizable</td>
</tr>
<tr>
<td>Increased contrast enhancement, relative to hepatic parenchyma, on late arterial phase</td>
<td>Nonrim arterial phase hyper-enhancement</td>
</tr>
<tr>
<td>Washout during the later contrast phases and peripheral rim enhancement on delayed phase</td>
<td>Non peripheral washout</td>
</tr>
<tr>
<td>Maximum diameter increase of 50% documented on serial MRI or CT obtained 180 days or less apart</td>
<td>Threshold growth defined as size increase of a mass by &gt; 50% in &lt; 180 days on MRI or CT</td>
</tr>
<tr>
<td>Washout on portal venous/delayed phase</td>
<td>Non peripheral washout</td>
</tr>
<tr>
<td>Peripheral rim enhancement</td>
<td>Enhancing capsule</td>
</tr>
<tr>
<td>Ablated</td>
<td>Treated by locoregional therapy</td>
</tr>
</tbody>
</table>

Hepatocellular Carcinoma (HCC) Guidance

The Committee is proposing an update to HCC guidance that will simplify how candidates with a history of HCC who subsequently have an HCC recurrence should be considered by the NLRB.

---

6 See CT/MRI LI-RADS v2018 Core available at acr.org.

7 Table 1 does not include every change to HCC policy included in this proposal. Please review the Policy and Guidance section for all proposed changes.
In the current HCC guidance document, there are two sections related to candidates with a history of HCC that subsequently recurs. One section of the guidance document states that candidates with a history of unresected HCC more than two years ago that was completely treated, who then develop new or recurrent lesions should be considered the same as candidates with no history of HCC, as long as the transplant program is applying for the candidate’s initial MELD exception. In effect, this guidance recommends that these candidates wait the standard six-month period before receiving their full MELD exception (MMaT-3). It is important to reiterate that this section of the guidance document only applies to candidates for whom a transplant program is submitting an initial HCC exception. It does not apply to candidates who have been listed with an HCC exception for any amount of time.

There is a subsequent section which states that candidates with cirrhosis who present with T2 resectable HCC who undergo complete resection and develop T1 or T2 recurrence can be considered for a MELD exception without a six-month waiting period. During the previous public comment period, the Committee added language to this section of the guidance to make it clear that candidates with a history of HCC more than two years ago that was resected and recurs do not need to wait six months to receive a full MELD exception score.

However, upon further discussion, the Committee is now proposing to remove each of these sections and replace them with a single section that will handle all candidates with a history of HCC who subsequently have an HCC recurrence, regardless of the initial treatment method.

The updated guidance recommends that candidates who presented with T2 HCC, which was completely treated either by locoregional therapy or resection, but who then developed T1 or T2 recurrence and the transplant program is requesting an initial exception more than six months but less than 60 months following the initial treatment or resection be provided an exception score equal to MMaT-3 without the six-month delay.

Table 2 includes the two sections of guidance that the Committee is proposing be removed, as well as the proposed new guidance.

---

8 See Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exceptions for Hepatocellular Carcinoma (HCC). Available at https://optn.transplant.hrsa.gov/
9 Ibid.
10 Review of National Liver Review Board (NLRB) Diagnoses and Update to Alcohol Associated Diagnoses, OPTN Liver and Intestinal Organ Transplantation Committee, December 2021, Available at https://optn.transplant.hrsa.gov/
11 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, November 5, 2021. Available at https://optn.transplant.hrsa.gov/
Table 2: Proposed Changes to HCC Guidance

<table>
<thead>
<tr>
<th>Section 1 (Being Removed)</th>
<th>Section 5 (Being Removed)</th>
<th>NEW Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients who have a history of prior unresected HCC more than 2 years ago which was</td>
<td>Patients with cirrhosis who presented with stage T2 resectable HCC (one lesion &gt;2 cm and&lt;5</td>
<td>Patients who presented with stage T2 HCC (LI-RADS 5 or biopsy proven; one lesion &gt;2 cm and &lt;5</td>
</tr>
<tr>
<td>completely treated with no evidence of recurrence, who develop new or recurrent lesions</td>
<td>cm in size, or two or three lesions &gt;1 cm and ≤3 cm in size, based on resection specimen</td>
<td>cm in size, or two or three lesions &gt;1 cm and &lt;3 cm in size) which was</td>
</tr>
<tr>
<td>after 2 years should generally be considered the same as those with no prior HCC, in</td>
<td>pathology) who underwent complete resection but developed T1 (biopsy proven), or T2</td>
<td>treated by locoregional therapy or resected but developed T1 or T2 HCC (LI-RADS</td>
</tr>
<tr>
<td>order to determine the current stage suitability for an initial MELD exception, and initial</td>
<td>HCC (LI-RADS 5) following complete resection should be considered for MELD score</td>
<td>5 or biopsy proven) recurrence and the transplant program is requesting an</td>
</tr>
<tr>
<td>MELD exception score assignment.</td>
<td>exception, without a six month delay period. This includes candidates who initially</td>
<td>initial HCC exception more than 6 months but less than 60 months following</td>
</tr>
<tr>
<td></td>
<td>presented with T2 resectable HCC and who underwent complete resection more than 2 years.</td>
<td>initial treatment or resection are eligible for a MELD score exception</td>
</tr>
<tr>
<td></td>
<td></td>
<td>without a six month delay period.</td>
</tr>
</tbody>
</table>

The Committee intends for the updated guidance to allow a larger cohort of HCC candidates to bypass the six-month waiting period while still ensuring the appropriate HCC candidates are prioritized for transplant. In the proposed guidance, all candidates with a history of HCC that subsequently recurs will be considered similarly, instead of having different recommendations based on the initial treatment method. The updated guidance will allow for more flexible waitlist management, as transplant programs will be able to attempt other treatment methods for HCC patients before listing them for transplant and still be able to access MMaT-3 on a similar timeframe as if they were listed and requested an exception at the time of initial HCC presentation.

As an example, under the proposed guidance, consider a patient who presented with T2 HCC 28 months ago. The HCC is completely treated via locoregional therapy and there is no evidence of recurrence. The HCC then recurs and the patient is diagnosed with another T2 lesion. Under the guidance currently in place, if the transplant program then submitted an initial exception request for this candidate, he or she would need to wait six months to get an exception score equal to MMaT-3.

Alternatively, the program could have listed this candidate for transplant upon initial HCC occurrence, and there is a strong likelihood the candidate would have been transplanted. However, this would not have been the optimal outcome for the transplant system, as the program could have attempted treatment without resorting to transplant, thereby taking a liver that could have been offered to a candidate with no other treatment options besides transplantation. Under the proposed guidance, this candidate would be eligible for an exception equal to MMaT-3 without the six-month delay. The updated guidance will give transplant programs the latitude to attempt to treat candidates with HCC prior to registering them for transplant without the fear that the candidate’s HCC will recur and they will have lost time they would have been accruing on the waitlist.
The Committee chose the six to 60 month timeframe based on their clinical expertise. They are chose 60 months as the cutoff to ensure that the recurrence is not new lesions that is unrelated to the initial occurrence. They chose the six-month starting point to align with the six-month waiting period for HCC candidates and to ensure favorable tumor biology. The Committee considered the example of a candidate who presented with T2 HCC that was completely treated via resection with no evidence of recurrence. The HCC then recurs four months after the initial presentation. The Committee did not think it was appropriate for this candidate to bypass the six-month waiting period. However, the transplant program could monitor the candidate for two months to ensure favorable tumor biology and then submit an exception to bypass the six-month waiting period and access an exception equal to MMaT-3 at the time of the initial exception.

It is also important to remember that these proposed changes are in the HCC guidance document and not OPTN policy. Because the changes are in guidance, transplant programs still have the ability to request exceptions for candidates outside the specific criteria if they believe the candidate needs a higher score or should bypass the six-month waiting period.

This aspect of the proposal was supported throughout public comment and the Committee did not make any post-public comment changes.

Ischemic Cholangiopathy (IC) Guidance

Diffuse ischemic cholangiopathy is a complication associated with DCD liver transplant. The current NLRB guidance recommends that candidates with a prior DCD transplant who demonstrate two or more of the following criteria within 12 months of transplant should be considered for an exception:

- Persistent cholestasis as defined by abnormal bilirubin (greater than 2 mg/dL)
- Two or more episodes of cholangitis with an associated bacteremia requiring hospital admission
- Evidence of non-anastomotic biliary strictures not responsive to further treatment

However, the current guidance does not recommend a specific exception score for these candidates. The Committee is proposing that the NLRB consider a score equal to MMaT for the candidates meeting these criteria, which is higher than most other exception scores. The Committee is proposing the higher score for these candidates to ensure they are able to access a high quality donor in time for re-transplant.

---

12 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, October 20, 2021. Available at https://optn.transplant.hrsa.gov/
13 Ibid.
14 Ibid.
15 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, November 5, 2021. Available at https://optn.transplant.hrsa.gov/
17 Ibid.
18 Ibid.
19 The majority of NLRB exceptions scores for adults is MMaT-3.
20 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, October 20, 2021. Available at https://optn.transplant.hrsa.gov/
The Committee reviewed data on candidates re-listed or re-transplanted after receiving a DCD donor liver. As Figure 1 depicts, this data showed that waitlist mortality rates for candidates re-listed for a liver had higher waitlist mortality than candidates with no previous transplant, but there was no significant difference in waitlist mortality rate between candidates re-listed after receiving a DCD transplant as opposed to a non-DCD transplant.

![Figure 1: Waiting List Mortality Rates for Adult Liver Transplant Candidates by Previous Transplant Group, 2015-2020](image)

The Committee believes it is appropriate to provide candidates with IC an exception score equal to MMaT so that these candidates can access a high quality donor and be listed ahead of other, less urgent exception diagnoses. In addition, the Committee agrees that the higher exception score might incentivize transplant programs to use more DCD donors.

While this aspect of the proposal was generally supported throughout public comment, some community members questioned whether the higher score is appropriate given that there does not seem to be a difference in waitlist mortality between candidates who previously received a DCD versus a non-DCD donor liver. The Committee discussed this feedback but ultimately agreed that it was appropriate to recommend a higher score for candidates meeting the criteria for an IC so they are able to access a high-quality donor quickly and to incentivize DCD transplantation.

---

21 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, October 1, 2021. Available at https://optn.transplant.hrsa.gov/
22 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, October 20, 2021. Available at https://optn.transplant.hrsa.gov/
23 Ibid.
24 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, April 4, 2022. Available at https://optn.transplant.hrsa.gov/
Finally, the Committee is proposing a number of updates to the guidance for candidates with PLD. The current guidance states that candidates with PLD with severe symptoms and any of the following criteria should be considered for a MELD exception:\textsuperscript{25}

- Hepatic decompensation
- Concurrent hemodialysis
- Glomerular Filtration Rate (GFR) less than 20 ml/min
- Patient with a prior kidney transplant
- Moderate to severe protein calorie malnutrition

The current guidance then recommends that liver-alone candidates meeting these criteria receive a score of MMaT-3 and liver-kidney candidates receive a score equal to MMaT.\textsuperscript{26}

The Committee is recommending a number of improvements to this guidance. First, the updated guidance adds language to make it clear that only candidates with PLD who are not clinically eligible for resection/fenestration or alternative therapy should be considered for an exception.\textsuperscript{27} The updated guidance also requires the presence of any of the qualifying comorbidities to be related to the candidate’s PLD. This will ensure a causal relationship between the candidate’s liver disease and the qualifying comorbidity.\textsuperscript{28} The Committee is recommending that “severe portal hypertensive complications” be added to the hepatic decompensation criterion.\textsuperscript{29}

In addition, the updated guidance includes more objective criteria to define moderate to severe protein calorie malnutrition. When the Committee last updated PLD guidance in 2020, they added “moderate to severe protein calorie malnutrition” as a qualifying comorbidity and debated if and how it should be more objectively defined to ensure only those candidates meeting the criteria are approved for an exception.\textsuperscript{30} However, the Committee did not reach a consensus on how to further define moderate to severe protein calorie malnutrition at that time.\textsuperscript{31} After additional review, the Committee is now defining moderate to severe protein calorie malnutrition by requiring a registered dietician to document the malnutrition using any of the following methods:

- Modified Global Leadership Initiative on Malnutrition (GLIM) Phenotypic criteria
- American Society for Enteral and Parenteral Nutrition (ASPEN) criteria
- Nutrition Focused Physical Exam (NFPE)
- Subjective Global Assessment (SGA-C score)

\textsuperscript{25} See Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exception Review. Available at https://optn.transplant.hrsa.gov/
\textsuperscript{26} Ibid.
\textsuperscript{27} See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, November 5, 2021. Available at https://optn.transplant.hrsa.gov/
\textsuperscript{28} Ibid.
\textsuperscript{29} See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, October 20, 2021. Available at https://optn.transplant.hrsa.gov/
\textsuperscript{30} Further Enhancements to the National Liver Review Board, OPTN Liver and Intestinal Organ Transplantation Committee, December 2020, Available at https://optn.transplant.hrsa.gov/
\textsuperscript{31} Ibid.
These tests include the standard methods by which a registered dietician would measure moderate to severe protein calorie malnutrition in a patient. The updated guidance will make it more likely that only those candidates with documented malnutrition will be able to access a MELD exception. The Committee does not intend for the updated definition to create an undue documentation burden on transplant programs or preclude any candidates who would have previously been approved for an exception. The inclusion of the multiple documentation methods is intended to give transplant teams the ability to use whichever is their preferred method.

The Committee is also proposing the addition of sarcopenia as a qualifying comorbidity. This new criterion will allow candidates with severe sarcopenia as documented with skeletal muscle index related to their PLD to access an exception. The addition of this new qualifying comorbidity reflects the fact that sarcopenia has been shown to be associated with chronic liver disease and is a prognostic factor for liver transplant candidates.

The Committee is also proposing the removal of language that is not needed and confusing. Removing this language does not substantively change the guidance but makes it more clear and understandable for the NLRB and transplant programs.

Finally, the Committee is proposing that the NLRB provide all candidates meeting the criteria for a PLD exception with an exception score equal to MMaT. The Committee agreed that liver involvement (with or without kidney involvement) is what drives this patient population’s mortality risk and therefore, all PLD candidates should be provided the same exception score.

This aspect of the proposal was supported throughout public comment and the Committee is not recommending any post-public comment changes.

---

32 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, November 5, 2021. Available at https://optn.transplant.hrsa.gov/


38 Ibid.


41 See OPTN Liver and Intestinal Organ Transplantation Committee meeting summary, November 5, 2021. Available at https://optn.transplant.hrsa.gov/

42 Ibid.

Overall Sentiment from Public Comment

The proposal was out for public comment from January 27, 2022 to March 23, 2022. The proposal was presented at 11 regional meetings and received additional feedback on the OPTN website. The proposal was presented to the OPTN Transplant Coordinators Committee, who supported the proposal.

Overall, the proposal did not receive any negative feedback but commenters did suggest changes to certain aspects of the proposal. Commenters were particularly supportive of the proposed changes to HCC policy and guidance. Many commenters also supported the proposed changes to IC guidance, although some commenters did not agree with the proposal to recommend candidates with IC be provided a score equal to MMaT.

The American Society of Transplantation (AST), the American Society of Transplant Surgeons (ASTS), and NATCO all supported the proposal.

The proposal was supported at all regional meetings. Public comment sentiment from each of the 11 OPTN regions is shown in Figure 2.

Figure 2: Sentiment at Regional Meetings

---

44 This chart shows the sentiment for the public comment proposal. Sentiment is reported by the participant using a 5-point Likert scale (1-5 representing Strongly Oppose to Strongly Support). Sentiment for regional meetings only includes attendees at that regional meeting. Region 6 uses the average score for each institution. The circles after each bar indicate the average sentiment score and the number of participants is in the parentheses.
Public comment sentiment by member type is below in Figure 3.45

The proposal before the Board includes some minor, non-substantive post-public comment changes but, due to overwhelming support, no major changes were made because of public comment.

**Compliance Analysis**

**NOTA and OPTN Final Rule**

The OPTN issues the *Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exception Review* and *Guidance to Liver Transplant Programs and the National Liver Review Board for Adult MELD Exceptions for Hepatocellular Carcinoma (HCC)* for the operation of the NLRB.46 This guidance will support the operation of the NLRB by assisting the reviewers with evaluating exception requests. The OPTN Final Rule requires the Board to establish performance goals for allocation policies, including “reducing inter-transplant program variance” in performance indicators.47 The changes to these guidance documents will assist in reducing inter-transplant program variance in the types of cases reviewed and approved by the NLRB by facilitating more consistent review of exception cases.

The Committee submits the proposed changes to policy under the authority of NOTA, which states, “The Organ Procurement and Transplantation Network shall...establish...medical criteria for allocating organs and provide to members of the public an opportunity to comment with respect to such criteria...”48, and the OPTN Final Rule, which states “The OPTN Board of Directors shall be responsible for developing...policies for the equitable allocation for cadaveric organs.”49 The Final Rule requires that when developing policies for the equitable allocation of cadaveric organs, such policies must be developed “in accordance with §121.8,” which requires that allocation policies “(1) Shall be based on sound medical judgment; (2) Shall seek to achieve the best use of donated organs; (3) Shall preserve the

---

45 This chart shows the sentiment for the public comment proposal. Sentiment is reported by the participant using a 5-point Likert scale (1-5 representing Strongly Oppose to Strongly Support). Sentiment by member type includes all comments regardless of source (regional meeting, committee meeting, online, fax, etc.) The circles after each bar indicate the average sentiment score and the number of participants is in the parentheses.

46 2019 OPTN Contract Task 3.2.4: Development, revision, maintenance, of OPTN Bylaws, policies, standards and guidelines for the operation of the OPTN.

47 42 C.F.R. §121.8(b)(4)

48 42 USC §274(b)(2)(B).

49 42 CFR §121.4(a).
ability of a transplant program to decline an offer of an organ or not to use the organ for the potential recipient in accordance with §121.7(b)(4)(d) and (e); (4) Shall be specific for each organ type or combination of organ types to be transplanted into a transplant candidate; (5) Shall be designed to avoid wasting organs, to avoid futile transplants, to promote patient access to transplantation, and to promote the efficient management of organ placement;... (8) Shall not be based on the candidate’s place of residence or place of listing, except to the extent required by paragraphs (a)(1)-(5) of this section.”

This proposal:

- Is based on sound medical judgment because it is an evidenced-based change relying on the collective clinical experience of the Committee to align the terminology with LI-RADs.
- Is designed to promote patient access to transplantation by giving similarly situated candidates equitable opportunities to receive an organ offer by making the requirements for HCC exception requests clearer and thus more consistently applied.
- Is not based on the candidate’s place of residence or place of listing

This proposal also preserves the ability of a transplant program to decline an offer or not use the organ for a potential recipient, and it is specific to an organ type, in this case liver.

Although the proposal outlined in this briefing paper addresses certain aspects of the Final Rule listed above, the Committee does not expect impacts on the following aspects of the Final Rule:

- Seeks to achieve the best use of donated organs
- Is designed to avoid wasting organs
- Is designed to avoid futile transplants
- Promotes the efficient management of organ placement

**OPTN Strategic Plan**

*Improve equity in access to transplants:* This proposal will increase equity in access to transplant by improving the likelihood that all candidates are appropriately reviewed for MELD or PELD exception requests.

---

50 42 CFR §121.8(a)(1).
51 42 CFR §121.8(a)(5).
52 42 CFR §121.8(a)(8).
53 42 CFR §121.8(a)(3).
54 42 CFR §121.8(a)(4).
55 42 CFR §121.8(a)(2).
56 42 CFR §121.8(a)(5).
57 Id.
58 Id.
Implementation Considerations

Potential Impact on Select Patient Populations

The proposed changes to NLRB guidance documents will impact the HCC, IC, and PLD candidate populations. The proposed changes to HCC guidance should make it easier for candidates with a history of HCC that subsequently recurs to receive an exception for MMaT-3 without the six-month wait. However, for candidates who were initially treated with resection, the updated guidance, which requires the exception request to be submitted between six and 60 months after initial HCC occurrence, is a bit more limiting. In current guidance, there is no such timeframe and any candidate with a history of resected HCC that subsequently recurs can access an exception for MMaT-3 regardless of the time between the initial occurrence and the exception request. However, the Committee does not expect the timeframe included in the updated guidance to have a meaningful impact on access to transplant for these candidates. More generally, a higher number of HCC candidates whose HCC has recurred should be able to receive an exception without the six month delay.

In addition, the proposed change to IC guidance will increase the exception scores provided to IC candidates, which will improve their access to transplant.

Finally, the proposed changes to PLD guidance will provide higher exception scores to liver alone candidates, improving their access to transplant. The addition of sarcopenia as a qualifying comorbidity should increase the number of candidates receiving a MELD exception for PLD. The Committee does not expect the updated definition of moderate to severe protein calorie malnutrition to preclude any candidates from accessing an exception who previously would have qualified without the objective definition.

No exception candidates will lose a current exception at the time of implementation of the updated guidance. However, NLRB reviewers and transplant programs will need to consult the updated guidance for initial exceptions and extension requests submitted after implementation.

The proposed changes to HCC policy will not impact any select patient population, as the change does not alter which candidates will meet the criteria for an HCC exception in OPTN policy. The Committee discussed if any population would be disadvantaged by the policy changes or if any transition procedures are needed and no such population or procedures were identified.59

Member and OPTN Operations

The proposed changes to HCC policy will need to be updated in the OPTN Computer System. This will include updating data labels and the reasons for which HCC exception requests do not meet standard criteria. These changes will be made on historic forms as well.

Relevant guidance documents and policy language will need to be updated. No changes in the OPTN Computer System are required for the updated guidance documents but the HCC policy updates will

59 42 C.F.R. § 121.8(d). The Final Rule requires the OPTN to “consider whether to adopt transition procedures that would treat people on the waiting list and awaiting transplantation prior to the adoption or effective date of the revised policies no less favorably than they would have been treated under the previous policies” whenever organ allocation policies are revised.
require changes to the OPTN Computer System. All changes will be communicated to the community prior to implementation. Transplant programs and NLRB reviewers will need to be aware of the changes.

*Operations affecting Histocompatibility Laboratories*
This proposal will have no operational impact on histocompatibility laboratories.

*Operations affecting Organ Procurement Organizations*
This proposal will have no operational impact on organ procurement organizations.

*Operations affecting Transplant Hospitals*
Transplant programs will need to be familiar with the proposed changes to NLRB policy and guidance when submitting exception requests for candidates.

*Operations affecting the OPTN*
The proposed changes to HCC policy will need to be implemented in the OPTN Computer System. Relevant guidance documents and policy language will need to be updated. The OPTN will provide a policy notice that will communicate any changes prior to becoming effective and will provide educational resources as appropriate.

**Projected Fiscal Impact**

*Projected Impact on Histocompatibility Laboratories*
No impact.

*Projected Impact on Organ Procurement Organizations*
No impact.

*Projected Impact on Transplant Hospitals*
Transplant hospitals will need to train staff on updated guidance documents for MELD exceptions.

*Projected Impact on the OPTN*
The OPTN Contractor estimates 695 hours for implementation. Implementation will involve HCC changes to be updated in the OPTN Computer System, updating guidance documents, communication efforts, and provision of educational resources. The OPTN Contractor estimates 132 hours for ongoing support. Ongoing support will involve answering member questions and monitoring at six and twelve months post-implementation.
Post-implementation Monitoring

Member Compliance

The Final Rule requires that allocation policies “include appropriate procedures to promote and review compliance including, to the extent appropriate, prospective and retrospective reviews of each transplant program’s application of the policies to patients listed or proposed to be listed at the program.”

This proposal will not change current routine monitoring of OPTN members. At transplant hospitals, site surveyors will continue to review a sample of medical records, and any material incorporated into the medical record by reference, to verify that data reported in the OPTN Computer System are consistent with source documentation, including qualifying criteria for standardized MELD or PELD exceptions or exception extensions.

Policy Evaluation

The Final Rule requires that allocation policies “be reviewed periodically and revised as appropriate.”

Using pre- and post-policy implementation comparisons, the following metrics will be analyzed at 6 months and 12 months post implementation, as requested by the NLRB subcommittee. The following metrics, and any others subsequently requested by the NLRB subcommittee, will be evaluated:

- Count of exception forms submitted with an ischemic cholangiopathy diagnosis and distribution of MELD or PELD score requested relative to median MELD at transplant
- Count of transplants with an ischemic cholangiopathy exception diagnosis and distribution of allocation MELD or PELD score at transplant
- Count of exception forms submitted with a polycystic liver disease diagnosis and distribution of MELD or PELD score requested relative to median MELD at transplant
- Count of transplants with a polycystic liver disease exception diagnosis and distribution of allocation MELD or PELD score at transplant

Conclusion

This proposal includes changes to HCC policy, as well as the guidance documents for HCC, IC, and PLD. The updated HCC policy will align OPTN terminology with the terminology used by radiologists responsible for HCC imaging. This will create consistency in the liver transplant community. The proposed change to HCC guidance creates a more equitable pathway for candidates with a history of HCC who subsequently recur to access a MELD exception equal to MMaT-3 without the six-month delay. The updated IC guidance includes a higher score for candidates meeting the criteria in guidance so these candidates can access re-transplant more quickly. And finally, the changes to PLD guidance include a more objective definition for moderate to severe protein calorie malnutrition, the addition of sarcopenia as a qualifying comorbidity, the removal of unnecessary language, and a recommendation that all candidates meeting the criteria be considered for and exception score equal to MMaT.

60 42 CFR §121.8(a)(7).
61 42 CFR §121.8(a)(6).
Together, these changes will create a more efficient and equitable system for reviewing MELD exception requests.
Policy and Guidance Language

Proposed new language is underlined (example) and language that is proposed for removal is struck through (example). Heading numbers, table and figure captions, and cross-references affected by the numbering of these policies will be updated as necessary.

9.5.I Requirements for Hepatocellular Carcinoma (HCC) MELD or PELD Score Exceptions

Upon submission of the first exception request, a candidate with hepatocellular carcinoma (HCC) will receive a score according to Policy 9.5.I.vii: Extensions of HCC Exceptions if the candidate meets the criteria according to Policies 9.5.I.i through 9.5.I.vi.

9.5.I.i Initial Assessment and Requirements for HCC Exception Requests

Prior to applying for a standardized MELD or PELD exception, the candidate must undergo a thorough assessment that includes all of the following:

1. An evaluation of the number and size of lesions before locoregional therapy that meet Class 5 criteria using a dynamic contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI)
2. A CT of the chest to rule out metastatic disease. This is only required prior to applying for an initial exception. A CT of the chest is not required for exception extensions.
3. A CT or MRI to rule out any other sites of extrahepatic spread or macrovascular involvement
4. An indication that the candidate is not eligible for resection
5. An indication whether the candidate has undergone locoregional therapy
6. The candidate’s alpha-fetoprotein (AFP) level

The transplant hospital must maintain documentation of the radiologic images and assessments of all OPTN Class 5 lesions in the candidate’s medical record. If growth criteria are used to classify a lesion as HCC, the radiology report must contain the prior and current dates of imaging, type of imaging, and measurements of the lesion.

For those candidates who receive a liver transplant while receiving additional priority under the HCC exception criteria, the transplant hospital must submit the Post-Transplant Explant Pathology Form to the OPTN within 60 days of transplant. If the Post-Transplant Explant Pathology Form does not show evidence of HCC or liver-directed therapy for HCC, the transplant program must also submit documentation or imaging studies confirming HCC at the time of assignment.

The Liver and Intestinal Organ Transplantation Committee will review the submitted
documentation or imaging studies when more than 10 percent of the Post-
Transplant Explant Pathology Forms submitted by a transplant program in a one-
year period do not show evidence of HCC or liver-directed therapy for HCC.

9.5.I.ii Eligible Candidates Definition of T2 Lesions Stage

Candidates with T2 HCC lesions are eligible for a standardized MELD or PELD exception if they have an alpha-fetoprotein (AFP) level less than or equal to 1000 ng/mL. T2 stage is defined as candidates with and either of the following:

- One Class 5 lesion greater than or equal to 2 cm and less than or equal to 5 cm in size.
- Two or three Class 5 lesions each greater than or equal to 1 cm and less than or equal to 3 cm in size.

A candidate who has previously had an AFP level greater than 1000 ng/mL at any time must qualify for a standardized MELD or PELD exception according to Policy 9.5.I.iv: Candidates with Alpha-fetoprotein (AFP) Levels Greater than 1000.

9.5.I.iii Lesions Eligible for Downstaging Protocols

Candidates are eligible for a standardized MELD or PELD exception if, before completing local-regional therapy, they have lesions that meet one of the following criteria:

- One Class 5 lesion greater than 5 cm and less than or equal to 8 cm
- Two or three Class 5 lesions that meet all of the following:
  - at least one lesion greater than 3 cm
  - each lesion less than or equal to 5 cm, and
  - a total diameter of all lesions less than or equal to 8 cm
- Four or five Class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm

For candidates who meet the downstaging criteria above and then complete local-regional therapy, their residual viable lesions must subsequently meet the size requirements for T2 lesions stage according to Policy 9.5.I.ii: Eligible Candidates Definition of T2 Lesions Stage to be eligible for a standardized MELD or PELD exception. Downstaging to meet eligibility requirements for T2 lesions stage must be demonstrated by dynamic-contrast enhanced CT or MRI performed after local-regional therapy. Candidates with lesions that do not initially meet the downstaging protocol inclusion criteria who are later downstaged and then meet eligibility for T2 lesions stage are not automatically eligible for a
standardized MELD or PELD exception and must be referred to the NLRB for consideration of a MELD or PELD exception.

9.5.I.iv Candidates with Alpha-fetoprotein (AFP) Levels Greater than 1000

Candidates with lesions meeting T2 criteria according to Policy 9.5.I.ii Eligible Candidates Definition of T2 Lesions Stage but with an alpha-fetoprotein (AFP) level greater than 1000 ng/mL may be treated with local-regional locoregional therapy. If the candidate’s AFP level falls below 500 ng/mL after treatment, the candidate is eligible for a standardized MELD or PELD exception as long as the candidate’s AFP level remains below 500 ng/mL. Candidates with an AFP level greater than or equal to 500 ng/mL following local-regional locoregional therapy at any time must be referred to the NLRB for consideration of a MELD or PELD exception.

9.5.I.v Requirements for Dynamic Contrast-enhanced CT or MRI of the Liver

CT scans and/or MRIs performed for a Hepatocellular Carcinoma (HCC) MELD or PELD score exception request must be interpreted by a radiologist at a transplant hospital. If the scan is inadequate or incomplete lesion cannot be categorized due to image degradation or omission, then the lesion will be classified as OPTN Class 0 Not categorizable (NC) and imaging must be repeated or completed to receive an HCC MELD or PELD exception.

9.5.I.vi Imaging Requirements for Class 5 Lesions

Lesions found on images of cirrhotic livers imaging in patients at risk for HCC are classified according to Table 9-9. The imaging criteria within the table apply only to observations which do not represent benign lesions or non-HCC malignancy (i.e. targetoid or LR-M) by imaging.

Table 9-9: Classification System for Lesions Seen on Imaging of Cirrhotic Livers

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-NC – Not Categorizable</td>
<td>Incomplete or technically inadequate study due to image degradation or omission</td>
</tr>
<tr>
<td>5A</td>
<td>1. Maximum diameter of at least 1 cm and less than 2 cm, as measured on late arterial or portal phase images.</td>
</tr>
<tr>
<td></td>
<td>2. Increased contrast enhancement, relative to hepatic parenchyma, on late arterial phase. Nonrim arterial phase hyper-enhancement</td>
</tr>
<tr>
<td></td>
<td>3. Either of the following:</td>
</tr>
<tr>
<td>Class</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>• Washout during the later contrast phases and peripheral rim enhancement on delayed phase <strong>Nonperipheral washout</strong>&lt;br&gt;• Biopsy</td>
</tr>
<tr>
<td>5A-g</td>
<td>Must meet <em>all</em> of the following:&lt;br&gt;1. Maximum diameter of at least 1 cm and less than 2 cm, as measured on late arterial or portal phase images.&lt;br&gt;2. Increased contrast enhancement, relative to hepatic parenchyma, on late arterial phase. <strong>Nonrim arterial phase hyper-enhancement</strong>&lt;br&gt;3. Maximum diameter increase of at least 50% documented on serial MRI or CT obtained 180 days or less apart. <strong>Threshold growth defined as size increase of a mass by ≥ 50% in ≤ 180 days on MRI or CT</strong></td>
</tr>
<tr>
<td>5B</td>
<td>Must meet <em>all</em> of the following:&lt;br&gt;1. Maximum diameter of at least 2 cm and less than or equal to 5 cm, as measured on late arterial or portal phase images.&lt;br&gt;2. Increased contrast enhancement, relative to hepatic parenchyma, on late hepatic arterial images. <strong>Nonrim arterial phase hyper-enhancement</strong>&lt;br&gt;3. <em>One of the following:</em>&lt;br&gt;   a. Washout on portal venous/delayed phase. <strong>Nonperipheral washout</strong>&lt;br&gt;   b. Peripheral rim enhancement. <strong>Enhancing capsule</strong>&lt;br&gt;   c. Maximum diameter increase, in the absence of ablation, by 50% or more and documented on serial MRI or CT obtained 180 days or less apart. Serial imaging and measurements must be performed on corresponding contrast phases. <strong>Threshold growth defined as size increase of a mass by ≥ 50% in ≤ 180 days on MRI or CT</strong>&lt;br&gt;   d. Biopsy.</td>
</tr>
<tr>
<td>5T</td>
<td><em>Any Class 5A, 5A-g, 5B lesion that was automatically approved upon initial request or extension and has subsequently been ablated, treated by locoregional therapy.</em></td>
</tr>
</tbody>
</table>

### 9.5.I.vii Extensions of HCC Exceptions

A candidate with an approved exception for HCC is eligible for automatic approval of an extension if the transplant program enters a MELD or PELD Exception Score Extension Request that contains the following:

1. Documentation of the tumor *stage* using a CT or MRI
2. The type of treatment if the number of tumors decreased since the last request
3. The candidate’s alpha-fetoprotein (AFP) level

A CT of the chest to rule out metastatic disease is not required after the initial exception request.

The candidate’s exception extension will then be automatically approved unless any of the following occurs:

- The candidate’s lesions progress beyond T2 criteria, according to 9.5.1.ii: Eligible Candidates Definition of T2 Lesions Stage
- The candidate’s alpha-fetoprotein (AFP) level was less than or equal to 1,000 ng/mL on the initial request but subsequently rises above 1,000 ng/mL
- The candidate’s AFP level was greater than 1,000 ng/mL, the AFP level falls below 500 ng/mL after treatment but before the initial request, then the AFP level subsequently rises to greater than or equal to 500 ng/mL
- The candidate’s tumors have been resected since the previous request
- The program requests a score different from the scores assigned in Table 9-10.

When a transplant program submits either an initial exception request or the first extension request for a liver candidate at least 18 years old at the time of registration that meets the requirements for a standardized MELD score exception, the candidate will appear on the match run according to the calculated MELD score.

A candidate who meets these requirements for a MELD or PELD score exception for HCC will receive a score according to Table 9-10 below.

### Table 9-10: HCC Exception Scores

<table>
<thead>
<tr>
<th>Age</th>
<th>Age at registration</th>
<th>Exception Request</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least 18 years old</td>
<td>At least 18 years old</td>
<td>Initial and first extension</td>
<td>Calculated MELD</td>
</tr>
<tr>
<td>At least 18 years old</td>
<td>At least 18 years old</td>
<td>Any extension after the first extension</td>
<td>3 points below MMaT</td>
</tr>
<tr>
<td>At least 12 years old</td>
<td>Less than 18 years old</td>
<td>Any</td>
<td>40</td>
</tr>
<tr>
<td>Less than 12 years old</td>
<td>Less than 12 years old</td>
<td>Any</td>
<td>40</td>
</tr>
</tbody>
</table>
Guidance to Liver Transplant Programs and the National Liver Review Board for:

Adult MELD Exceptions for Hepatocellular Carcinoma (HCC)

Background
A liver candidate receives a MELD\textsuperscript{62} or, if less than 12 years old, a PELD\textsuperscript{63} score that is used for liver allocation. The score is intended to reflect the candidate’s disease severity, or the risk of 3-month mortality without access to liver transplant. When the calculated score does not reflect the candidate’s medical urgency, a liver transplant program may request an exception score. A candidate that meets the criteria for one of nine diagnoses in policy is approved for a standardized MELD exception.\textsuperscript{64} If the candidate does not meet criteria for standardized exception, the request is considered by the Review Board.

The OPTN Liver and Intestinal Organ Transplantation Committee (hereafter, “the Committee”) has developed guidance for adult MELD exceptions for Hepatocellular Carcinoma (HCC). This guidance document is intended to provide recommendations for the review board considering HCC cases which are outside standard policy.

This guidance replaces any independent criteria that OPTN regions used to request and approve exceptions, commonly referred to as “regional agreements.” Review board members and transplant centers should consult this resource when considering MELD exception requests for adult candidates with the following diagnoses.

Recommendation

1. Patients with the following are contraindications for HCC exception score:
   - Macro-vascular invasion of main portal vein or hepatic vein
   - Extra-hepatic metastatic disease
   - Ruptured HCC
   - T1 stage HCC

While in most cases, ruptured HCC and primary portal vein branch invasion of HCC would be contraindications, some patients who remain stable for a prolonged (minimum of 12 months) interval after treatment for primary portal vein branch invasion or after ruptured HCC may be suitable for consideration.

\textsuperscript{62}Model for End-Stage Liver Disease
\textsuperscript{63}Pediatric End-Stage Liver Disease
\textsuperscript{64}Policy 9.3.C: Specific MELD/PELD Exceptions, Organ Procurement and Transplantation Network Policies.
Evidence for the use of immunotherapy as a down-staging or bridging therapy is preliminary. However, based on the published data in transplant and non-transplant setting, the use of immunotherapy does not preclude consideration for an HCC exception.\textsuperscript{65}

- Patients who have a history of prior unresected HCC more than 2 years ago which was completely treated with no evidence of recurrence, who develop new or recurrent lesions after 2 years should generally be considered the same as those with no prior HCC, in order to determine the current stage suitability for an initial MELD exception, and initial MELD exception score assignment.

- Patients beyond standard criteria who have continued progression while waiting despite LRT locoregional are generally not acceptable candidates for HCC MELD exception.

- Patients with AFP>1000 who do not respond to treatment to achieve an AFP below 500 are not eligible for standard MELD exception, and must be reviewed by the HCC review board to be considered. In general, these patients are not suitable for HCC MELD exception but may be appropriate in some cases.

- Patients with HCC beyond standard down-staging criteria who are able to be successfully downstaged to T2 may be appropriate for MELD exception, as long as there is no evidence of metastasis outside the liver, or macrovascular invasion, or AFP >1,000. Imaging should be performed at least 4 weeks after last down-staging treatment. Patients must still wait for 6 months from the time of the first request to be eligible for an HCC exception score.

- Patients with cirrhosis who presented with stage T2 resectable HCC (one lesion >2 cm and <5 cm in size, or two or three lesions >1 cm and <3 cm in size, based on resection specimen pathology) who underwent complete resection but developed T1 (biopsy proven), or T2 HCC (LI-RADS 5) following complete resection should be considered for MELD score exception, without a six month delay period. This includes candidates who initially presented with T2 resectable HCC and who underwent complete resection more than 2 years ago.

- Patients who presented with stage T2 HCC (LI-RADS 5 or biopsy proven; one lesion >2 cm and <5 cm in size, or two or three lesions >1 cm and <3 cm in size) which was treated by locoregional therapy or resected but developed T1 or T2 HCC (LI-RADS 5 or biopsy proven) recurrence and the transplant program is requesting an initial HCC exception more than 6 months but less than 60 months following initial treatment or resection are eligible for a MELD score exception without a six month delay period.

Patients with cirrhosis and HCC beyond T2 but within generally accepted criteria for down-staging (such as up to 5 lesions, total tumor volume <8 cm based on resection pathology) who underwent complete

resection with negative margins and developed T1 (biopsy proven) or T2 recurrence (LI-RADS 5) may also be considered for MELD score exception for HCC. Because the larger tumor size, the 6 month delay is appropriate to ensure favorable tumor biology.

Recommendations for Dynamic Contrast-enhanced CT or MRI of the Liver

<table>
<thead>
<tr>
<th>Feature</th>
<th>CT scans should meet the below specifications:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scanner type</strong></td>
<td>Multidetector row scanner</td>
</tr>
<tr>
<td><strong>Detector type</strong></td>
<td>Minimum of 8 detector rows and must be able to image the entire liver during brief late arterial phase time window</td>
</tr>
<tr>
<td><strong>Slice thickness</strong></td>
<td>Minimum of 5 mm reconstructed slice thickness; thinner slices are preferable especially if multiplanar reconstructions are performed</td>
</tr>
<tr>
<td><strong>Injector</strong></td>
<td>Power injector, preferably dual chamber injector with saline flush and bolus tracking recommended</td>
</tr>
<tr>
<td><strong>Contrast injection rate</strong></td>
<td>3 mL/sec minimum, better 4-6 mL/sec with minimum of 300 mg I/mL or higher, for dose of 1.5 mL/kg body weight</td>
</tr>
<tr>
<td><strong>Mandatory dynamic phases on contrast-enhanced MDCT</strong></td>
<td></td>
</tr>
<tr>
<td>1. <strong>Late arterial phase</strong>: artery fully enhanced, beginning contrast enhancement of portal vein</td>
<td></td>
</tr>
<tr>
<td>2. <strong>Portal venous phase</strong>: portal vein enhanced, peak liver parenchymal enhancement, beginning contrast enhancement of hepatic veins</td>
<td></td>
</tr>
<tr>
<td>3. <strong>Delayed phase</strong>: variable appearance, greater than 120 seconds after initial injection of contrast</td>
<td></td>
</tr>
<tr>
<td><strong>Dynamic phases (Timing)</strong></td>
<td>Use the bolus tracking or timing bolus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Feature</th>
<th>MRIs should meet the below specifications:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scanner type</strong></td>
<td>1.5T Tesla or greater main magnetic field strength. Low field magnets are not suitable.</td>
</tr>
<tr>
<td><strong>Coil type</strong></td>
<td>Phased array multichannel torso coil, unless patient-related factors precludes its use.</td>
</tr>
<tr>
<td><strong>Minimum sequences</strong></td>
<td>Pre-contrast and dynamic post gadolinium T1-weighted gradient echo sequence (3D preferable), T2 (with and without fat saturation), T1-weighted in and out of phase imaging.</td>
</tr>
<tr>
<td><strong>Injector</strong></td>
<td>Dual chamber power injector with bolus tracking recommended.</td>
</tr>
<tr>
<td><strong>Contrast injection rate</strong></td>
<td>2-3 mL/sec of extracellular gadolinium chelate that does not have dominant biliary excretion, preferably resulting in vendor-recommended total dose.</td>
</tr>
<tr>
<td>Feature</td>
<td>MRIs should meet the below specifications:</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mandatory dynamic phases on contrast-</td>
<td>1. Pre-contrast T1W: do not change scan parameters for post contrast imaging.</td>
</tr>
<tr>
<td>enhanced MRI</td>
<td>2. Late arterial phase: artery fully enhanced, beginning contrast enhancement of portal vein.</td>
</tr>
<tr>
<td></td>
<td>4. Delayed phase: variable appearance, greater than 120 seconds after initial injection of contrast.</td>
</tr>
<tr>
<td>Dynamic phases (Timing)</td>
<td>The use of the bolus tracking method for timing contrast arrival for late arterial phase imaging is preferable. Portal vein phase images should be acquired 35 to 55 seconds after initiation of late arterial phase. Delayed phase images should be acquired 120 to 180 seconds after the initial contrast injection.</td>
</tr>
<tr>
<td>Slice thickness</td>
<td>5 mm or less for dynamic series, 8 mm or less for other imaging.</td>
</tr>
<tr>
<td>Breath-holding</td>
<td>Maximum length of series requiring breath-holding should be about 20-seconds with a minimum matrix of 128 x 256. Technologists must understand the importance of patient instruction about breath-holding before and during scan.</td>
</tr>
</tbody>
</table>
Diffuse Ischemic Cholangiopathy

Diffuse ischemic cholangiopathy is a complication associated with donation after circulatory cardiac death (DCD) donors. Analysis of waitlist outcomes for patients re-listed after undergoing liver transplant from a DCD donor demonstrates that these patients have a similar or improved waitlist survival compared to donation after brain death (DBD) candidates who are re-listed with similar MELD scores. However, patients with ischemic cholangiopathy may have significant morbidity and require multiple repeat biliary interventions and repeat hospitalizations for cholangitis. Despite similar waitlist outcomes as DBD donor liver recipients who are listed for retransplant, the Committee supports increased priority for prior DCD donor liver recipients to encourage use of DCD livers when appropriate.

In addition, analyses has shown that patients with a prior DCD transplant and an approved MELD score exception had an improved survival compared to those who never had an exception approved. Patients with biliary injuries and need for biliary interventions also have been demonstrated to have an increased risk of graft loss and death. Therefore, patients with a prior DCD transplant that who demonstrated two or more of the following criteria within 12 months of transplant should be considered are eligible for MELD exception equivalent to MMaT:

- Persistent cholestasis as defined by abnormal bilirubin (greater than 2 mg/dl)
- Two or more episodes of cholangitis with an associated bacteremia requiring hospital admission
- Evidence of non-anastomotic biliary strictures not responsive to further treatment

---

Polycystic Liver Disease (PLD)

Certain patients with PLD who are not clinically eligible for resection/fenestration or alternative therapy may benefit from MELD exception points. Indication for an exception include those with PCLD(PLD(Mayo type D or C)) with severe symptoms related to PLD plus any of the following:

- Hepatic decompensation or severe portal hypertensive complications
- Concurrent hemodialysis
- GFR less than 20 ml/min
- Patient with a prior kidney transplant
- Moderate to severe protein calorie malnutrition as documented by a registered dietician using any of the following:
  - Modified Global Leadership Initiative on Malnutrition (GLIM) Phenotypic criteria
  - American Society for Enteral and Parenteral Nutrition (ASPEN) criteria
  - Nutrition Focused Physical Exam (NFPE)
  - Subjective Global Assessment (SGA-C score)
- Severe sarcopenia as documented with skeletal muscle index (SMI < 39 cm²/m² in women and < 50 cm²/m² in men) or equivalent

Transplant programs should provide the following criteria when submitting exceptions for PLD. The Review Board should consider the following criteria when reviewing exception applications for candidates with PLD.

1. Management of PLD

<table>
<thead>
<tr>
<th>PLD Classification – Mayo Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Types</td>
</tr>
<tr>
<td>Symptom</td>
</tr>
<tr>
<td>Cyst Findings</td>
</tr>
<tr>
<td>Spared Remnant Volume</td>
</tr>
<tr>
<td>PV/HV Occlusion</td>
</tr>
</tbody>
</table>

2. Surgical Management of PLD

- Indications:
  - Types C* and D and at least 2 of the following:
    - Hepatic decompensation
    - Concurrent renal failure (dialysis)

---

b. Compensated comorbidities

Note: Prior resection/fenestration, alternative therapy precluded.

Patients who meet the criteria above should be considered eligible for a MELD exception similar to other policy-assigned exception scores, equivalent to MMaT.

When a candidate also meets the medical eligibility criteria for liver-kidney allocation as described in OPTN Policy 9.9: Liver-Kidney Allocation and is registered on the kidney waitlist, the candidate should be considered for a MELD exception score similar to the score assigned to candidates with primary hyperoxaluria in OPTN Policy.